

METABOLIC HEALTH



Retatrutide: The Honest Guide

You have seen the numbers. You have probably seen the vials for sale too. Maybe one is already in your fridge.

Swipe

THE UNDERGROUND VIAL

Unknown Purity, Unknown Contents, No Monitoring

The underground version means unknown purity, wrong or contaminated contents, non-sterile vials, guesswork dosing and zero medical monitoring. You are betting your health on a vial no one has verified.

THE DRUG CLASS

More Levers Has Meant More Weight Lost

Semaglutide acts on one receptor, GLP-1.
Tirzepatide acts on two, GIP and GLP-1.
Retatrutide adds the third, glucagon.

PHASE 2, NEJM 2023

Close to a Quarter of Starting Weight

In 338 adults over 48 weeks: average body-weight loss of 24.2% at the 12 mg dose and 22.8% at 8 mg, versus just 2.1% on placebo. This trial was funded by Eli Lilly, the company developing the drug.

PHASE 3, TRIUMPH-1

About 28% Average Body-Weight Loss

In May 2026 Eli Lilly reported the first results: roughly 2,339 adults with obesity, and without diabetes, followed for 80 weeks. At the highest dose, average loss of about 28%, compared with about 2.2% on placebo.

PHASE 3, THE RESPONDERS

At the Highest Dose, Close to Half Lost 30% or More

About 45% of that group lost 30% or more of their body weight, a level of loss that until recently was mostly seen after weight-loss surgery.

THE BOTTOM LINE

Strong Results Are Not Approval

Retatrutide is still investigational. Not approved by the EMA, the Spanish AEMPS or the FDA, and not yet sold in licensed pharmacies. Positive trial data come before approval, not with it.

WHERE WE STAND



Approved and In Pharmacies First

We do not sell, source, or prescribe underground or grey-market retatrutide. We provide honest information and medical oversight. Once a pharmaceutical-grade, approved version is available in licensed pharmacies, our double board-certified specialist will be able to prescribe and supervise it properly.